Demographics and baseline characteristics of patients with light-chain amyloidosis (AL)
| Characteristic . | Value . |
|---|---|
| No. of patients | 35 |
| Male/female* | 24 (69)/11 (31) |
| Age, y† | 64 (38-90) |
| Clonality, λ* | 26 (74) |
| Number of organs involved* | |
| 1-2 | 23 (66) |
| 3-4 | 12 (34) |
| Kidney involvement* | 30 (86) |
| Heart involvement* | 18 (51) |
| Liver involvement* | 5 (14) |
| Peripheral nerve involvement* | 9 (26) |
| Serum albumin, g/dL† | 2.9 (1.0-5.7) |
| Serum creatinine, mg/dL† | 1.3 (0.5-7.0) |
| Serum alkaline phosphatase, IU/L† | 100 (49-459) |
| β2-Microglobulin, mg/L† | 3.6 (1.3-15.0) |
| Urine total protein, g/24 h† | 5.0 (0-45) |
| Serum M-component, g/dL† | 0.7 (0-2.9) |
| Urine M-component, g/24 h† | 0.2 (0-9.5) |
| Serum free light chain, mg/L† | 159 (22-513) |
| Serum cardiac troponin T, ng/mL† | 0.01 (0-0.3) |
| NT-ProBNP, pg/mL† | 1773 (27-14 365) |
| PCs by morphology† | 4.0 (0.1-24.0) |
| PCs by MFC immunophenotyping† | 1.4 (0.1-15.0) |
| Characteristic . | Value . |
|---|---|
| No. of patients | 35 |
| Male/female* | 24 (69)/11 (31) |
| Age, y† | 64 (38-90) |
| Clonality, λ* | 26 (74) |
| Number of organs involved* | |
| 1-2 | 23 (66) |
| 3-4 | 12 (34) |
| Kidney involvement* | 30 (86) |
| Heart involvement* | 18 (51) |
| Liver involvement* | 5 (14) |
| Peripheral nerve involvement* | 9 (26) |
| Serum albumin, g/dL† | 2.9 (1.0-5.7) |
| Serum creatinine, mg/dL† | 1.3 (0.5-7.0) |
| Serum alkaline phosphatase, IU/L† | 100 (49-459) |
| β2-Microglobulin, mg/L† | 3.6 (1.3-15.0) |
| Urine total protein, g/24 h† | 5.0 (0-45) |
| Serum M-component, g/dL† | 0.7 (0-2.9) |
| Urine M-component, g/24 h† | 0.2 (0-9.5) |
| Serum free light chain, mg/L† | 159 (22-513) |
| Serum cardiac troponin T, ng/mL† | 0.01 (0-0.3) |
| NT-ProBNP, pg/mL† | 1773 (27-14 365) |
| PCs by morphology† | 4.0 (0.1-24.0) |
| PCs by MFC immunophenotyping† | 1.4 (0.1-15.0) |